Elicio Therapeutics, Inc. (ELTX): debt financing — Elicio Therapeutics secures $10M senior secured note from board-affiliated investor

Elicio Therapeutics, Inc.

Issued $10M promissory note to GKCC (controlled by board member); interest rate up to 12.5%.
Warrant to purchase 103,225 shares at $7.75 issued; immediately exercisable, 5-year term.
Proceeds plus current cash expected to fund operations into Q1 2026.
AMPLIFY-7P Phase 2 interim analysis for ELI-002 in PDAC anticipated in Q3 2025.
Note matures June 3, 2028; 24-month interest-only period with lump-sum interest payment.

item 1.01 item 2.03 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Elicio Therapeutics, Inc. incurred senior notes of $10.0 million with GKCC, LLC at Prime Rate plus 5.00%, maximum 12.5% per annum maturing June 3, 2028.

Instrument: senior notes
Principal: $10.0 million
Counterparty: GKCC, LLC
Rate: Prime Rate plus 5.00%, maximum 12.5% per annum
Maturity: June 3, 2028
Event: incurrence

Exact text from the filing

On June 3, 2025, Elicio Therapeutics, Inc. (the “Company”) entered into a note purchase agreement (the “Note Purchase Agreement”) pursuant to which the Company issued a Senior Secured Promissory Note due June 3, 2028 (the “Promissory Note”) in the principal amount of $10.0 million (the “Note Financing”).

View on SEC.gov

Browse all debt financings →

Elicio Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001601485-25-000096

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.